(Q57588792)

English

A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial

scientific article published on 05 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

phase I clinical trial

0 references

Neisseria meningitidis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Stephen B. Lambert

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

M D Nissen

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

D Roberton

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

W C Gruber

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

T R Jones

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Arora

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

language of work or name

0 references

publication date

5 August 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

30

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

43

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

6163-6174

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Global epidemiology of meningococcal disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

A review of vaccine research and development: meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Immunologic response of man to group B meningococcal polysaccharide vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Vaccine potential of the Neisseria meningitidis 2086 lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Functional significance of factor H binding to Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

New frontiers in meningococcal vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Neisseria meningitidis B vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Meningococcal surrogates of protection--serum bactericidal antibody activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Human immunity to the meningococcus. I. The role of humoral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine in Children Aged 16???24 Months

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.065

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.07.065

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22871351%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57588792&oldid=2032408910"